Michael Campbell, Ph.D. received his doctoral degree in Cancer Biology from Stanford University where he remained as a postdoctoral fellow in Oncology. Dr. Campbell was appointed Assistant Professor of Surgery at Stanford University in 1992. He joined the UCSF faculty as Assistant Professor of Surgery in 1997.
Dr. Campbell's areas of interest in research include breast neoplasms, cancer vaccines, immunotherapy, immunologic adjuvants, immunologic and biological factors, gene therapy, immunology, and breast cancer.
Most recent publications from a total of 48
Candell L, Campbell MJ, Shen WT, Gosnell JE, Clark OH, Duh QY. Ultrasound-guided methylene blue dye injection for parathyroid localization in the reoperative neck. World J Surg. 2014 Jan; 38(1):88-91. View in PubMed
Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, Van't Veer L, Berry D, Esserman LJ. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114. View in PubMed
Campbell MJ, McCoy KL, Shen WT, Carty SE, Lubitz CC, Moalem J, Nehs M, Holm T, Greenblatt DY, Press D, Feng X, Siperstein AE, Mitmaker E, Benay C, Tabah R, Oltmann SC, Chen H, Sippel RS, Brekke A, Vriens MR, Lodewijk L, Stephen AE, Nagar S, Angelos P, Ghanem M, Prescott JD, Zeiger MA, Aragon Han P, Sturgeon C, Elaraj DM, Nixon IJ, Patel SG, Bayles SW, Heneghan R, Ochieng P, Guerrero MA, Ruan DT. A multi-institutional international study of risk factors for hematoma after thyroidectomy. Surgery. 2013 Dec; 154(6):1283-91. View in PubMed
Campbell MJ, Seib CD, Gosnell J. Vandetanib and the management of advanced medullary thyroid cancer. Curr Opin Oncol. 2013 Jan; 25(1):39-43. View in PubMed
Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ. Biology of breast cancer in Nigerian women: a pilot study. Ann Afr Med. 2012 Jul-Sep; 11(3):169-75. View in PubMed
Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann Surg Oncol. 2012 Nov; 19(12):3979-86. View in PubMed
Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011 Nov; 130(2):635-44. View in PubMed
Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100. View in PubMed
Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-11. View in PubMed
Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(1):137-44. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.